Locati LD, Galbiati D, Calareso G, et al. - Since treatment of cases with recurrent and/or metastatic (R/M) salivary gland adenoid cystic carcinoma (ACC) continues to be an unmet need, researchers undertook this study with 28 patients with R/M ACC, including 26 evaluable patients, to report outcomes following administration of oral lenvatinib at a dose of 24 mg/day in patients with R/M disease with a history of clinical or symptomatic disease progression within 6 months and a maximum of 1 prior line of chemotherapy or a multiple kinase inhibitor. Three partial responses (11.5%) were noted in 26 evaluable patients. Four of 20 patients with stable disease had a target lesion decreases between 23% to 28%. Treatment-related adverse events were commonly experienced. The median overall survival was 27 months, progression-free survival was 9.1 months, and the duration of response was 3.1 months. Findings are indicative of the modest activity of lenvatinib in ACC. The reported toxicities were common but manageable. Quality of life deterioration in some domains was observed.